Inhibiting Triggering Receptor Expressed on Myeloid Cells 1 Signaling to Ameliorate Skin Fibrosis

SignaBlok > News

SignaBlok > News

Inhibiting Triggering Receptor Expressed on Myeloid Cells 1 Signaling to Ameliorate Skin Fibrosis

Bale et al. JCI Insight. 2024

TREM-1 and TREM-2 as Therapeutic Targets: Clinical Challenges and Perspectives

Sigalov AB. Front Immunol. 2024

SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of sepsis, pulmonary inflammation and fibrosis at the 2025 Respiratory Innovation Summit (RIS) and American Thoracic Society (ATS) International Conference

SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SignaBlok released PHS-Financial Conflict of Interest (FCOI) Policy

SARS-CoV-2 may affect the immune response via direct inhibition of T cell receptor: Mechanistic hypothesis and rationale

Sigalov AB. Biochimie. 2022

SignaBlok presented preclinical data on the use of ligand-independent TREM-1 blockers as innate immune checkpoint inhibitors to overcome cancer immunotherapy resistance at the CICON23

SignaBlok awarded NEI / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitors for neovascular retinal diseases

SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new mechanism-based TREM-1 therapy for acute respiratory distress syndrome

Triggering receptor expressed on myeloid cells-1 (TREM-1) contributes to Bordetella pertussis inflammatory pathology

Gallop D, Scanlon K et al. Infect Immun. 2021